Replication-incompetent adenoviruses (Ad) carrying the herpes simplex thymidine kinase (HSVtk) gene have been used in a number of human cancer gene therapy trials, however transduction has generally been limited to a small minority of tumor cells. To solve this problem, replication-competent adenoviral vectors carrying transgenes such as HSVtk have been developed. However, contradictory evidence exists regarding the efficacy of these new vectors. Accordingly, we constructed and tested a replication-competent E3-deleted adenoviral vector containing the HSVtk suicide gene driven by the endogenous E3 promoter (Ad.wt.tk). This virus
Introduction
Recombinant adenovirus-based gene therapy is being used in the treatment of human tumors in diseases such as malignant mesothelioma, 1 breast cancer, 2 bronchogenic lung cancer, 3 head and neck malignancies, 4 and prostate cancer. 5 In many of these clinical trials, transgene expression has been identified, however, transduction has generally been limited to a small minority of tumor cells. Even using approaches where cytotoxic effects are extended to non-transduced cells via a 'bystander effect' (ie in the herpes simples virus thymidine kinase/ ganciclovir (HSVtk/GCV) system), tumor cell killing has still been limited. Additional strategies must thus be developed if this approach to cancer gene therapy is to become a viable therapeutic option.
One such strategy is the use of replication-competent adenoviral vectors to carry therapeutic transgenes ('armed' viruses). 6, 7 In the 1950s and 1960s 'wild-type' replication-competent viruses were used to treat a variety of malignancies via direct intratumoral injection. 8, 9 These therapies were abandoned due to limited responses and the development of better chemotherapeutic agents. However, with the recent advances in the development of gene therapy vectors, specifically the ability to intro- showed high level production of the HSVtk transgene and was more efficacious than a non-replicating virus in vitro, after injection into flank tumors, and against established intraperitoneal tumors. However, addition of ganciclovir (GCV) therapy to cells or tumor-bearing animals treated with the replicating vector containing the HSVtk suicide gene did not result in increased cell killing. Our results indicate that addition of HSVtk to a replicating Ad virus will not likely be useful in augmenting antitumor effects. Gene Therapy duce potentially therapeutic genes and the ability to restrict replication to tumor cells, replication-competent adenoviruses are being re-evaluated. 10, 11 There are at least two reasons for potential increased efficacy of replication-competent adenoviruses carrying therapeutic transgenes. First, there are likely to be direct lytic effects of the virus. This hypothesis is supported by recent preclinical and clinical data using replication-selective adenoviruses that do not carry transgenes. 12 The prototypical replication competent virus, ONYX-015, that has a deletion in the adenovirus E1B region enabling it to replicate preferentially in tumor cells, has been demonstrated to exert tumor lytic effects and spread within tumors following intratumoral injection. 13, 14 This virus is currently in phase 1 and 2 clinical trials. 7 Other replication-selective adenoviral vectors have been generated by inserting tumor-selective promoters (such as the prostate specific antigen promoter) into the virus to drive the E1A genes, [15] [16] [17] and at least one of these vectors (Calydon Virus 787) is in clinical trials for prostate cancer. 12 The second potential advantage of the 'armed' viruses would be their ability to amplify the spread of transgene. For example, in the HSVtk/GCV system, even only one or two rounds of replication could potentially allow a much larger number of tumor cells to express the enzyme and thus be susceptible to GCV-mediated killing. 18 Although the superiority of armed viruses seems to be a reasonable hypothesis, contradictory evidence exists in the literature regarding the actual efficacy of replicationcompetent viruses expressing the HSVtk gene. Two initial reports by Wildner et al 19, 20 presented data using an E1B-deleted adenovirus containing the HSVtk transgene in the E1 region driven by a CMV promoter (Ad.TK RC ). In these studies, lytic effects were seen with the Ad.TK RC virus alone in melanoma, cervical and colon carcinoma xenografts, and tumor killing was augmented by the addition of high-dose ganciclovir. However, in more recent publications by Morris and Wildner 21, 22 using wild-type replicating adenoviruses containing an HSVtk transgene, but with no E1B deletion (Ad.OW34 and Ad.OW37), no augmentation of killing was observed after the addition of GCV. Similar to these latter findings, Freytag et al 23 and Rogulski et al 24 designed a virus that also lacked E1B, but contained a cytosine-deaminase/herpes simplex thymidine kinase fusion gene (FGR virus). The FGR virus had good antitumor effects after injection into cervical carcinoma xenografts, however, addition of GCV did not augment the efficacy of the virus. Interestingly, augmented killing effects were seen when both 5-fluorocytosine and GCV were added.
In view of this controversy and with the growing interest in armed replication-competent vectors in a variety of tumor settings, 25 we developed and tested a replicationcompetent E3-deleted adenoviral vector containing the HSVtk suicide gene driven by the endogenous E3 promoter. In addition to testing the vector in subcutaneous flank models of multiple tumors, we also evaluated the efficacy and potential toxicity of a regionally delivered replication-competent adenovirus (introduced via intraperitoneal injection) in mice with and without the addition of ganciclovir. Our results indicate that addition of HSVtk/GCV to the replicating virus does not augment antitumor effects.
Results
Analysis of Ad.wt.tk viral replication and DNA expression Ad.wt.tk was designed to be a fully replication-competent adenovirus similar to wild-type virus, but containing the HSVtk transgene. It was constructed by deleting the E3 region from wild-type virus and inserting the HSVtk transgene driven by the endogenous E3 promoter (see Materials and methods). Viral replication of Ad.wt.tk was demonstrated in the human lung cancer cell line A549 using a standard plaque assay as demonstrated in Figure 1 . A large vial burst of 5 × 10 11 p.f.u./ml was Gene Therapy 30 h after infection with Ad.wt.tk. HSVtk protein was assessed by immunoblotting. Large amounts of HSVtk protein expression were clearly detectable at 6 h after infection, indicating that TK was expressed early in infection (data not shown). These data are consistent with regulation of the HSVtk transgene by the endogenous E3 promoter.
Cytotoxicity assays
In order to determine the effect of the replication-competent vector expressing thymidine kinase on in vitro cell viability, we infected several tumor cell lines including REN (mesothelioma), A549 (lung cancer), and C33a (cervical carcinoma) with Ad.wt.tk and Ad. 
E3
− .tk plus GCV (gray bars), however significantly increased toxicity (70% killing) was seen after the addition of Ad.wt.tk (white bars) (P Ͻ 0.01, ANOVA). At this MOI, addition of GCV increased cell killing (P Ͻ 0.01, ANOVA). At a dose of 10 MOI, there was marked cell killing with Ad.E1 .tk vector at all the MOIs evaluated. However, in these cell lines, the addition of GCV did not provide for any significant increase in the in vitro cytotoxicity over the replicationcompetent vector alone.
These studies demonstrate an increased cytotoxicity of the Ad.wt.tk over the Ad.E1
.tk/GCV system in these human cell lines. In one cell line (REN) there was increased cell killing after the addition of GCV to cells treated with Ad.wt.tk virus at an MOI of 1, however in the other cell lines, GCV did not provide an increase in Ad.wt.tk cytotoxicity.
Treatment of established subcutaneous tumors with intratumoral injection
To define the in vivo efficacy of the Ad.wt.tk vector, subcutaneous tumors were established in the flanks of nude mice using the lung cancer cell line A549. On day 9 after tumor injection, macroscopic tumors were measured and treated with a single intratumoral injection of vector or control solution. In one experiment, tumors were excised and weighed 7 days after vector injection. In a second experiment, tumor size was determined every 4-5 days using calipers. Tumor growth in the Ad.wt.tk-treated group was compared with media alone and Ad.E1 (1) size, as measured by calipers, was validated by removing the tumors on day 32 and weighing them.
Similar results were seen in a second short-term flank model using C33a tumor cells ( Figure 5 ). In this study, the tumors appeared more sensitive to treatment with almost complete tumor disappearance after 7 days of therapy. Evaluation of tumor weights was thus performed 1 week after virus injection. Treatment with Ad.wt.tk resulted in significantly decreased tumor size compared with media control, Ad.E1
.tk/GCV groups (P Ͻ 0.05, ANOVA). Again, the addition of GCV did not improve the therapeutic benefit of Ad.wt.tk.
Intraperitoneal tumor model
An intraperitoneal tumor model in SCID mice was evaluated to define better the efficacy of localized delivery of Ad.wt.tk, as would be used to treat malignant mesothelioma or ovarian cancer. As a control, we compared the effects of a replication-incompetent Ad vector expressing HSVtk. In these experiments, we used an E1/E4-deleted Ad.HSVtk. We have previously characterized this vector and shown that it behaves virtually identically to the E1/E3-deleted version.
26 A549 cells were injected intraperitoneally. Macroscopic A549 tumors were documented .tk and survival was compared with media control. Two groups of mice received i.p. GCV therapy (50 mg/kg/day) for 7 days following adenoviral treatment.
The survival curves are shown in Figure 6 . The overall logrank test comparing the five groups yielded P = 0.027. Examination of the individual survival curves indicated that this difference was primarily due to reduced survival in the control mice and those treated with Ad.E1 −
E4
− .tk without GCV. Both of these groups had a median survival of about 40 days and were dead by 7 weeks. Animals treated with Ad.E1 − E4 − .tk plus GCV had a signifi- cant increase in survival as compared with controls (median survival 57 days, P = 0.0032), but all animals died by 76 days. These results are similar to our previous studies of mesothelioma and lung cancer. 27 Delivery of Ad.wt.tk led to a slightly different type of survival profile. In these animals, there was evidence of some early toxicity (at about 1 week after viral injection), but surviving animals had an increase in survival (median survival 52 days) with some animals living to 95-105 days. Although this result was not statistically significant from control animals using the log-rank test, this was due to the crossing of the survival curves of the Ad.wt.tk and control mice, due to early deaths in the Ad.wt.tk group. Importantly, the results for Ad.wt.tk plus GCV were nearly identical to those for Ad.wt.tk without GCV.
Discussion
The hypothesis tested in this study was that a replicationcompetent adenovirus 'armed' with the HSVtk transgene would be more effective in treating tumors than the 'unarmed' vector due to augmented spread of transgene. Somewhat surprisingly, our results do not support this paradigm. Despite high level production of the HSVtk transgene by the Ad.wt.tk vector (Figure 2 ), the addition of ganciclovir (GCV) did not augment in vitro cell killing in most cell lines (Figure 3) , did not result in further reductions in flank tumor size (Figures 4 and 5) , and did not increase survival in an intraperitoneal model of tumor when compared with vector administered without addition of GCV ( Figure 6 ).
Our results are consistent with those of Rogulski et al 24 who found that tumor cell killing in animals treated with an E1B-deleted replicating virus containing both the HSVtk and cytosine deaminase gene without prodrug therapy was the same as when animals were treated with vector plus GCV alone or vector plus 5-FC alone. Augmented tumor killing was only seen in those animals treated with both GCV and 5-FC. In this study, the reason for this finding was not determined for certain, however, Rogulski et al 24 showed that the HSVtk/GCV system was effective in inhibiting viral replication. Presumably a balance is reached between augmented GCV-induced cell killing due to production of toxic GCV metabolites versus the GCV-induced reduction of cell killing due to impaired viral replication. Our data, and that of Rogulski et al, 24 would suggest that loss of lytic killing by the virus offsets any benefits due to enhanced transgene spread.
Our results are somewhat different than the data originally reported by Wildner et al. 19, 20 These investigators found augmentation of antitumor effects by adding GCV therapy to an E1B-deleted adenovirus expressing HSVtk (Ad.TK RC ). In these original studies, extremely high doses of GCV were administered (100 mg/kg of GCV was given twice daily). However, the results of a more recent study using a similar E1B deleted virus (Ad.TK RC (II)) and treating with a much lower dose of GCV (10 mg/kg twice a day) were similar, suggesting that the GCV dose was not the reason for the difference in results. 22 Of more relevance, Morris and Wildner 21, 22 studied armed replicating viruses similar to the one used in this study (that is, adenoviruses without E1B deletions, but carrying the HSVtk transgene, Ad.OW34 and AdOW37) and found, in contrast to their previous results, that addition of GCV did not augment antitumor effects. This difference was attributed to the fact that the new vectors replicated more efficiently than the E1B-deleted virus and that GCV allowed termination of viral replication. Again, the key factor appears to be the balance between augmented GCV-induced cell killing due to production of toxic GCV metabolites versus the GCV-induced reduction of cell killing due to impaired viral replication. Our results are similar to the more recent studies of Morris and Wildner using the adenovirus without an E1B deletion.
Our data are also consistent with Morris and Wildner's findings after administering vector in an intracavitary fashion, 22 a route of delivery similar to that being used for ongoing clinical trials for mesothelioma and ovarian carcinoma. Both studies found significant antitumor effects of the replication-competent viruses given in this fashion. In our study, we observed no augmentation of effect by administration of GCV (Figure 6 ). Morris and Wildner actually found a higher mortality in animals treated with replication-competent virus plus GCV than in animals treated with replication-competent virus alone. 22 One interesting feature of our study, that may need to be investigated more carefully, was the early mortality that we noted in some of the tumor-bearing animals treated with the replication-competent virus. In preliminary studies, this mortality appears to be due to liver toxicity, however the mechanisms (ie role of the HSVtk transgene, the possibility of viral replication within the liver, or possible toxicity due to intraperitoneal cytokine release) of this injury are unknown and are currently under study. It should be noted that similar early toxicity was not seen in the Wildner and Morris study 22 using E1B-deleted or wild-type viruses expressing HSVtk or by Heise et al 28 examining the use of the Onyx-15 virus in intraperitoneal models of ovarian cancer in nude mice.
Although our data suggest that addition of HSVtk to replicating viruses is not likely to be therapeutically useful, the concept of 'armed' replicating vectors still has potential merit. Other suicide genes might be useful.
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The double suicide gene vectors described by Freytag et al appear to have merit. 23, 24 Other areas that hold potential value would be the inclusion of cytokines such as GM-CSF or IL-2, or anti-angiogenesis genes (endostatin or angiostatin) that might augment antitumor responses. 29 One important factor to keep in mind, however, is that although the potential efficacy of these viruses can be tested in existing mouse models, testing the safety of any replicating adenoviral vector will continue to be difficult since commonly used laboratory animals do not allow replication of the virus. 11, 25 In summary, a replicating adenoviral vector containing the HSVtk transgene appears to have efficacy against flank and intraperitoneal tumors. However, addition of ganciclovir therapy to a replicating vector containing the HSVtk suicide gene did not augment efficacy, despite the enhanced production of transgene. Addition of other types of transgenes to replicating vectors may provide a therapeutic advantage, however, each specific modification must be carefully evaluated.
Materials and methods

Cell lines
The human bronchioalveolar carcinoma A549 (ATCC No. CCL-185) and the human cervical squamous carcinoma cell line C33a (ATCC No. HTB-31) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). REN is a human malignant mesothelioma cell line isolated in our laboratory from a patient tumor specimen. 30 All cell lines were maintained in RPMI media supplemented with 10% FCS, 100 U/ml penicillin G, 100 g/ml streptomycin and 2 mm glutamine.
Adenoviral vector construction
The wild-type virus used in these studies was an Ad serotype 5 virus obtained from the vector core of the Institutive for Human Gene Therapy at the University of Pennsylvania.
The replication-incompetent E1/E3-deleted vector (Ad.E1 The replication-competent adenovirus containing the HSVtk transgene in the E3 region (Ad.wt.tk) was constructed by cloning a Kozak and a full-length HSVtk cDNA sequence cassette into the BamHI site flanking the deleted E3 region of the pAB27 plasmid (Microbix Biosystems, Toronto, Canada) to generate pAB27tk. pAB27 is a circularized adenoviral plasmid with large deletions of (1) Ad 5 sequences from bp 5788-24796; (2) E1 deletion from bp 354-3824; and (3) E3 deletion from bp 28133-30818. A multiple cloning sequence replaces the E3 deletion. cDNAs cloned into the multiple cloning site are under the control of the E3 promoter.
The full-length HSVtk cDNA was amplified by PCR from the pAd.RSV.tk 26 using sense and antisense primers engineered to contain BamHI ends. The product (1.3 kb) was gel purified, digested with BamHI and ligated to similarly digested and dephosphorylated plasmid, pAB27tk. The ligation product was transformed into DH5 ␣ cells and colonies analyzed for the tk plasmid DNA. The orientation of the tk cDNA was determined by restriction digestion and by nucleotide sequencing. Clones that were positive were next analyzed for expression of the TK protein. Positive clones were transfected into 293 cells using the lipofectin and 48 h later TK protein was detected by immunohistochemistry using rabbit polyclonal TK antibody, using the ABC Vector Lab Kit (Vector Laboratories, Burlingame, CA, USA).
To construct the replication-competent adenovirus, wild-type Ad5 DNA was digested with SpeI to generate two fragments: 29 and 7 kb long. The 29 kb fragment represents the left-hand side of the virus and is missing the E3 and E4 regions of the virus. Gel purified 29 kb fragment and pAB27tk plasmid were co-transfected into 293 cells with calcium phosphate and 24 h later overlayed with 1% agarose. Individual plaques that appeared within 9-15 days were isolated and amplified on 293 cells and analyzed for the TK protein by immunoblotting. Positive plaques were further subjected to three rounds of plaque purification. A single plaque that had been purified was scaled up in 293 cells and banded over a cesium chloride gradient. The particle to p.f.u. ratio was determined by a standard plaque assay in 293 cells and virus was stored at −70°C. Ad.wt.tk DNA was tested for contamination with wild-type virus by PCR analysis for the absence of E3 sequences. 
E3
− tk at 1 MOI in T-75 flasks. After a 4-h infection in serumfree media, the media was removed, the cells were washed with PBS and serum-containing media was replaced. The cells were harvested by scraping at the end of the 4-h infection (time 0) and at 24, 48 and 72 h. The cell pellets were resuspended in 10 mm Tris pH 8.0 and stored at −80°C. The viral particles were released from the cells by lysing the cells with three repeated freezethaw cycles and then centrifuging the cell debris from the supernatant. The cell lysates were then plaqued on 293 cells to determine the p.f.u. titer expressed as p.f.u./ml. The particle to p.f.u. ratio of all viruses was approximately 100.
Immunoblotting for HSVtk
Semi-quantitative immunoblots were performed comparing the production of the 44 kDa thymidine kinase protein by the replication-competent adenoviral vector (Ad.wt.tk) and the replication-incompetent virus (Ad.E1 − E3 − .tk). This approach has been previously described in detail.
31 A549 cells were infected in 2.0 ml of serum-free media at a multiplicity of infection of 0.1 and 10 for 4 h. The media was next aspirated and replaced with 5 ml of the serum-containing media. At varying time points, media was aspirated, cells were lysed in 4 × Lamelli buffer (0.125 m Tris-HCl pH 6.8, 4% SDS), and the DNA was sheared with an insulin syringe. Total protein was measured by the Lowry method. One hundred g of protein for each sample was boiled with sample buffer containing beta mercapto-ethanol and loaded on to a 12% SDS PAGE gel. Controls included on the gel were a positive control (Ad.E1 − E3 − .tk-infected 293 cells) and a negative control (uninfected A549 cells). Protein was electro-transferred on to a PVDF membrane and immuno-blotted with a rabbit polyclonal anti-HSVtk antibody at a dilution of 1/1000, followed by incubation with donkey anti-rabbit conjugated to HRP at a dilution of 1/10 000. The membrane was next incubated for 2 min in chemiluminescence (ECL) reagent (NEN Life Science Products, Boston, MA, USA) and exposed to ECL Hyperfilm (Amersham, Thousand Oaks, CA, USA) for visualization.
Determination of the kinetics of HSVtk protein production In order to determine the expression of the HSV.tk transgene cloned into the E3 site in the absence of DNA replication, we monitored TK protein expression in cells infected with the Ad.wt.tk virus and incubated with 1-␤-d-arabinosyl cytosine (ara-C) (Sigma, St Louis, MO, USA).
Three hundred thousand A549 cells were plated in two six-well plates in 2 ml of RPMI40 supplemented with 10% fetal calf serum. Twenty-four hours later, cells were infected in serum-free media with Ad.wt.tk at an MOI of 50 for 2 h following which the medium was removed and replaced with 10% serum-containing medium in one plate and with ara-C (100 g/ml) in the second plate. Cells were harvested from both plates 6, 18 and 30 h after infection, by scraping in 200 l of 2 × laemmli buffer and passed through a 27.5 G needle to shear the DNA. Total protein was quantified using the BCA (BioRad, Hercules, CA, USA) kit according to the manufacturer's instructions. Twenty micrograms of total protein was separated on 10% SDS-PAGE gel and electroblotted on to PVDF membrane. The blot was next processed for the detection of TK protein as described above.
In vitro cytotoxicity assays
To test the in vitro efficacy of the replication-competent Ad.wt.tk virus, subconfluent monolayers of tumor cells of REN, C33a, and A549 cells were infected in T25 flasks at 0.1, 1.0 and 10 MOI for 4 h in serum-free media. The cells were allowed to recover in media with 10% serum for 1 h after transfection, and then were plated on 96-well plates. REN cells were plated at a density of 5000 cells/well while C33a, and A549 cells were plated at 3000 cells/well. After a 24-h incubation following viral infection, the cell culture media in one-half of the plated cells was removed and replaced with media containing 20 m ganciclovir (GCV; Roche Laboratories, Nutley, NJ, USA). The cells were then incubated at 37°C and 5% CO 2 for 5 days at which time the control wells had reached confluency. The number of viable cells was then determined using a colorimetric cell proliferation assay that measures viable cell dehydrogenase activity. (CellTiter 96 Aqueous Non-radioactive MTS Cell Proliferation Assay; Promega, Madison, WI, USA). 
Animal studies
Effects of intratumoral injection is established subcutaneous lesions
Female homozygous NCR nude mice (6-8 weeks, approximately 25 g) were obtained from Taconic Laboratory (Germantown, NY, USA) and housed in the animal facility at the Wistar Institute (Philadelphia, PA, USA). To evaluate the effect of a replication-competent vector versus a replication-incompetent virus and the utility of the addition of ganciclovir, subcutaneous flank tumors were established using the A549 and C33a models. Five million A549 cells (in 250 l serum-free media) were injected subcutaneously bilaterally into the flanks. In one experiment (n = 10 tumors per group), tumor growth was assessed 7 days after vector injection by killing the animals and weighing the tumors. In the second experiment, tumor growth was monitored using calipers and tumor volume was computed using the formula for the volume of an ellipsoid, /6*W*L 2 . At 7 days, when mean tumor volume had reached approximately 80 mm 3 , the mice were randomized into the following treatment groups (n = 10 tumors/group): (1) media control; (2) Ad.E1 
E4
− tk (1 × 10 11 particles) followed by 6 days of i.p. ganciclovir (50 mg/kg/animal); (4) Ad.wt.tk (1 × 10 11 particles); and (5) Ad.wt.tk (1 × 10 11 particles) followed by 6 days of i.p. ganciclovir (50 mg/kg/animal). Mice were followed daily for survival.
Statistics
All of the in vitro cell viability data and the flank tumor data was expressed as mean ± standard error of the mean. Comparisons were made using ANOVA with appropriate post-hoc testing (Fisher's PLSD). Survival studies were analyzed using the Mantel-Cox log-rank test.
